newsfilter
← Latest News
GlobeNewswire·

ZyVersa Therapeutics Reports Third Quarter, 2024 Financial Results and Provides Business Update

KEY BUSINESS HIGHLIGHTS Phase 2a clinical trial for Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney disease expected to begin Q1-2025.New Obesity, Metabolic & Inflammatory Disease